Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 13/20 | 0.50 |
| ▸ | DUT | P33316 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150274 | 0.90 | P2RY6 (0.59) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL475344 | 0.86 | P2RY6 (0.51) | P2RY6DUTPOLA1P2RY2P2RY4 | |
| SCHEMBL9805678 | 0.85 | P2RY6 (0.50) | P2RY6DUTP2RY2P2RY4 | |
| Triphosphate SCHEMBL27589399 | 0.85 | P2RY6 (0.52) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL65485 | 0.83 | SLC28A1 (0.44) | P2RY6DUTP2RY2P2RY4 | |
| SCHEMBL27703606 | 0.83 | SLC28A1 (0.44) | P2RY6DUTP2RY2P2RY4 | |
| SCHEMBL7394363 | 0.83 | P2RY6 (0.46) | P2RY6DUTPOLA1P2RY2P2RY4 | |
| SCHEMBL11383197 | 0.81 | P2RY6 (0.46) | P2RY6DUTP2RY2P2RY4 | |
| SCHEMBL1129233 | 0.78 | P2RY6 (0.62) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL18486630 | 0.77 | P2RY2 (0.48) | P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139947-A1 | METHOD FOR ASSESSING SUSCEPTIBILITY OF A VIRUS TO TREATMENT BY MEASURING ENZYME ACTIVITY AND A SYSTEM THEREFORE | CAVIDI AB (SE) | 2021-05-13 | — | — | US | disclosed |
| CN-110832083-A | Method for evaluating sensitivity of virus to treatment by measuring enzyme activity and system thereof | 卡维迪有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-7875422-B2 | in an enveloped virus-infected mammalian individual by testing on an enzyme packed into an enveloped virus, such as HIV, recovered from a biological sample, such as blood or plasma | CAVIDI AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-7488577-B2 | non-radioactive assay in microtiter plate format enabling colorimetric or fluorimetric product detection for drug screening; solid phase synthesis | CAVIDI TECH AB (SE) | 2009-02-10 | — | — | US | disclosed |
| WO-2008024052-A1 | A METHOD AND A KIT FOR DETERMINATION OF AN ENZYME ACTIVITY INVOLVED IN METABOLIC PRODUCTION OF A DEOXYNUCLEOSIDE TRIPHOSPHATE AND USE THEREOF | RÖNNERBOL INTERNATIONAL AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1311672-B1 | tRNA-derived inhibitors of HIV reverse transcriptase | PRIMERT AB (SE) | 2006-03-01 | — | — | EP | disclosed |
| EP-1395676-B1 | VIRAL DRUG SUSCEPTIBILITY TESTING | CAVIDI TECH AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| EP-1395675-B1 | A METHOD FOR MEASURING DNA POLYMERIZATION AND APPLICATIONS OF THE METHOD | CAVIDI TECH AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| US-20040170958-A1 | Viral drug susceptibility testing | EUROPEAN INVESTMENT BANK (LU) | 2004-09-02 | — | — | US | disclosed |
| US-20040157230-A1 | Method for measuring dna polymerization and applications of the method | CAVIDI AB (SE) | 2004-08-12 | — | — | US | disclosed |
| US-20040053872-A1 | Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome | PRIMERT AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1395676-A1 | VIRAL DRUG SUSCEPTIBILITY TESTING | Cavidi Tech AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1395675-A1 | A METHOD FOR MEASURING DNA POLYMERIZATION AND APPLICATIONS OF THE METHOD | Cavidi Tech AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1311672-A1 | NEW SEQUENCES | Primert AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002103039-A1 | A METHOD FOR MEASURING DNA POLYMERIZATION AND APPLICATIONS OF THE METHOD | CAVIDI TECH AB (SE) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002103040-A1 | VIRAL DRUG SUSCEPTIBILITY TESTING | CAVIDI TECH AB (SE) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002016608-A1 | NEW SEQUENCES | PRIMERT AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| US-5053336-A | Monoclonal antibodies for the separate detection of halodeoxyuridines and method for their use | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053872-A1 | Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome | POLRMT, NSUN3, TARBP1 | P2RY6 2303/4885DUT 18/4885POLA1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.